PMC:7594251 / 41128-41958 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T39453","span":{"begin":530,"end":541},"obj":"Body_part"}],"attributes":[{"id":"A9134","pred":"fma_id","subj":"T39453","obj":"http://purl.org/sig/ont/fma/fma62863"}],"text":"At the time of writing, and to the best of our knowledge, there are three Food and Drug Administration (FDA)-approved drugs derived from the FBDD approach [221], and over 30 are in clinical trials [222]. The first marketed drug derived via the FBDD approach is vemurafenib [223]. Vemurafenib is also the first drug approved for treatment of BRAF-mutant cancer [224], and is reported to exhibit significant clinical benefit for patients with metastatic melanoma [224]. Venetoclax, a common drug used to treat patients with chronic lymphocytic leukemia [225], is considered the second drug to be discovered using the FBDD approach [221], and ribociclib, a CDK4 inhibitor, the third [221]. The names, structures, targets/applications, and clinical status of vemurafenib, venetoclax, ribociclib, and other drugs are listed in Table 2."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T27","span":{"begin":353,"end":359},"obj":"Disease"},{"id":"T28","span":{"begin":441,"end":460},"obj":"Disease"},{"id":"T29","span":{"begin":452,"end":460},"obj":"Disease"},{"id":"T30","span":{"begin":522,"end":550},"obj":"Disease"},{"id":"T31","span":{"begin":530,"end":550},"obj":"Disease"},{"id":"T32","span":{"begin":542,"end":550},"obj":"Disease"}],"attributes":[{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0005191"},{"id":"A29","pred":"mondo_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/MONDO_0005105"},{"id":"A30","pred":"mondo_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/MONDO_0004948"},{"id":"A31","pred":"mondo_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/MONDO_0005402"},{"id":"A32","pred":"mondo_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/MONDO_0005059"}],"text":"At the time of writing, and to the best of our knowledge, there are three Food and Drug Administration (FDA)-approved drugs derived from the FBDD approach [221], and over 30 are in clinical trials [222]. The first marketed drug derived via the FBDD approach is vemurafenib [223]. Vemurafenib is also the first drug approved for treatment of BRAF-mutant cancer [224], and is reported to exhibit significant clinical benefit for patients with metastatic melanoma [224]. Venetoclax, a common drug used to treat patients with chronic lymphocytic leukemia [225], is considered the second drug to be discovered using the FBDD approach [221], and ribociclib, a CDK4 inhibitor, the third [221]. The names, structures, targets/applications, and clinical status of vemurafenib, venetoclax, ribociclib, and other drugs are listed in Table 2."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T296","span":{"begin":480,"end":481},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T297","span":{"begin":552,"end":555},"obj":"http://purl.obolibrary.org/obo/CLO_0001196"},{"id":"T298","span":{"begin":652,"end":653},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"At the time of writing, and to the best of our knowledge, there are three Food and Drug Administration (FDA)-approved drugs derived from the FBDD approach [221], and over 30 are in clinical trials [222]. The first marketed drug derived via the FBDD approach is vemurafenib [223]. Vemurafenib is also the first drug approved for treatment of BRAF-mutant cancer [224], and is reported to exhibit significant clinical benefit for patients with metastatic melanoma [224]. Venetoclax, a common drug used to treat patients with chronic lymphocytic leukemia [225], is considered the second drug to be discovered using the FBDD approach [221], and ribociclib, a CDK4 inhibitor, the third [221]. The names, structures, targets/applications, and clinical status of vemurafenib, venetoclax, ribociclib, and other drugs are listed in Table 2."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T408","span":{"begin":118,"end":123},"obj":"Chemical"},{"id":"T409","span":{"begin":223,"end":227},"obj":"Chemical"},{"id":"T410","span":{"begin":261,"end":272},"obj":"Chemical"},{"id":"T411","span":{"begin":310,"end":314},"obj":"Chemical"},{"id":"T412","span":{"begin":489,"end":493},"obj":"Chemical"},{"id":"T413","span":{"begin":583,"end":587},"obj":"Chemical"},{"id":"T414","span":{"begin":659,"end":668},"obj":"Chemical"},{"id":"T415","span":{"begin":755,"end":766},"obj":"Chemical"},{"id":"T416","span":{"begin":768,"end":778},"obj":"Chemical"},{"id":"T417","span":{"begin":802,"end":807},"obj":"Chemical"}],"attributes":[{"id":"A408","pred":"chebi_id","subj":"T408","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A409","pred":"chebi_id","subj":"T409","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A410","pred":"chebi_id","subj":"T410","obj":"http://purl.obolibrary.org/obo/CHEBI_63637"},{"id":"A411","pred":"chebi_id","subj":"T411","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A412","pred":"chebi_id","subj":"T412","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A413","pred":"chebi_id","subj":"T413","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A414","pred":"chebi_id","subj":"T414","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A415","pred":"chebi_id","subj":"T415","obj":"http://purl.obolibrary.org/obo/CHEBI_63637"},{"id":"A416","pred":"chebi_id","subj":"T416","obj":"http://purl.obolibrary.org/obo/CHEBI_133021"},{"id":"A417","pred":"chebi_id","subj":"T417","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"At the time of writing, and to the best of our knowledge, there are three Food and Drug Administration (FDA)-approved drugs derived from the FBDD approach [221], and over 30 are in clinical trials [222]. The first marketed drug derived via the FBDD approach is vemurafenib [223]. Vemurafenib is also the first drug approved for treatment of BRAF-mutant cancer [224], and is reported to exhibit significant clinical benefit for patients with metastatic melanoma [224]. Venetoclax, a common drug used to treat patients with chronic lymphocytic leukemia [225], is considered the second drug to be discovered using the FBDD approach [221], and ribociclib, a CDK4 inhibitor, the third [221]. The names, structures, targets/applications, and clinical status of vemurafenib, venetoclax, ribociclib, and other drugs are listed in Table 2."}

{"project":"LitCovid-PubTator","denotations":[{"id":"542","span":{"begin":341,"end":345},"obj":"Gene"},{"id":"543","span":{"begin":654,"end":658},"obj":"Gene"},{"id":"544","span":{"begin":427,"end":435},"obj":"Species"},{"id":"545","span":{"begin":508,"end":516},"obj":"Species"},{"id":"546","span":{"begin":261,"end":272},"obj":"Chemical"},{"id":"547","span":{"begin":280,"end":291},"obj":"Chemical"},{"id":"548","span":{"begin":468,"end":478},"obj":"Chemical"},{"id":"549","span":{"begin":615,"end":619},"obj":"Chemical"},{"id":"550","span":{"begin":755,"end":766},"obj":"Chemical"},{"id":"551","span":{"begin":353,"end":359},"obj":"Disease"},{"id":"552","span":{"begin":452,"end":460},"obj":"Disease"},{"id":"553","span":{"begin":522,"end":550},"obj":"Disease"}],"attributes":[{"id":"A542","pred":"tao:has_database_id","subj":"542","obj":"Gene:673"},{"id":"A543","pred":"tao:has_database_id","subj":"543","obj":"Gene:1019"},{"id":"A544","pred":"tao:has_database_id","subj":"544","obj":"Tax:9606"},{"id":"A545","pred":"tao:has_database_id","subj":"545","obj":"Tax:9606"},{"id":"A546","pred":"tao:has_database_id","subj":"546","obj":"MESH:D000077484"},{"id":"A547","pred":"tao:has_database_id","subj":"547","obj":"MESH:D000077484"},{"id":"A548","pred":"tao:has_database_id","subj":"548","obj":"MESH:C579720"},{"id":"A550","pred":"tao:has_database_id","subj":"550","obj":"MESH:D000077484"},{"id":"A551","pred":"tao:has_database_id","subj":"551","obj":"MESH:D009369"},{"id":"A552","pred":"tao:has_database_id","subj":"552","obj":"MESH:D008545"},{"id":"A553","pred":"tao:has_database_id","subj":"553","obj":"MESH:D015451"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"At the time of writing, and to the best of our knowledge, there are three Food and Drug Administration (FDA)-approved drugs derived from the FBDD approach [221], and over 30 are in clinical trials [222]. The first marketed drug derived via the FBDD approach is vemurafenib [223]. Vemurafenib is also the first drug approved for treatment of BRAF-mutant cancer [224], and is reported to exhibit significant clinical benefit for patients with metastatic melanoma [224]. Venetoclax, a common drug used to treat patients with chronic lymphocytic leukemia [225], is considered the second drug to be discovered using the FBDD approach [221], and ribociclib, a CDK4 inhibitor, the third [221]. The names, structures, targets/applications, and clinical status of vemurafenib, venetoclax, ribociclib, and other drugs are listed in Table 2."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T8","span":{"begin":353,"end":359},"obj":"Phenotype"},{"id":"T9","span":{"begin":452,"end":460},"obj":"Phenotype"},{"id":"T10","span":{"begin":522,"end":550},"obj":"Phenotype"}],"attributes":[{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0002861"},{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0005550"}],"text":"At the time of writing, and to the best of our knowledge, there are three Food and Drug Administration (FDA)-approved drugs derived from the FBDD approach [221], and over 30 are in clinical trials [222]. The first marketed drug derived via the FBDD approach is vemurafenib [223]. Vemurafenib is also the first drug approved for treatment of BRAF-mutant cancer [224], and is reported to exhibit significant clinical benefit for patients with metastatic melanoma [224]. Venetoclax, a common drug used to treat patients with chronic lymphocytic leukemia [225], is considered the second drug to be discovered using the FBDD approach [221], and ribociclib, a CDK4 inhibitor, the third [221]. The names, structures, targets/applications, and clinical status of vemurafenib, venetoclax, ribociclib, and other drugs are listed in Table 2."}

{"project":"LitCovid-sentences","denotations":[{"id":"T286","span":{"begin":0,"end":203},"obj":"Sentence"},{"id":"T287","span":{"begin":204,"end":279},"obj":"Sentence"},{"id":"T288","span":{"begin":280,"end":467},"obj":"Sentence"},{"id":"T289","span":{"begin":468,"end":686},"obj":"Sentence"},{"id":"T290","span":{"begin":687,"end":830},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"At the time of writing, and to the best of our knowledge, there are three Food and Drug Administration (FDA)-approved drugs derived from the FBDD approach [221], and over 30 are in clinical trials [222]. The first marketed drug derived via the FBDD approach is vemurafenib [223]. Vemurafenib is also the first drug approved for treatment of BRAF-mutant cancer [224], and is reported to exhibit significant clinical benefit for patients with metastatic melanoma [224]. Venetoclax, a common drug used to treat patients with chronic lymphocytic leukemia [225], is considered the second drug to be discovered using the FBDD approach [221], and ribociclib, a CDK4 inhibitor, the third [221]. The names, structures, targets/applications, and clinical status of vemurafenib, venetoclax, ribociclib, and other drugs are listed in Table 2."}